Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 15, 2026, 2:09 PM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 553–576 of 3,856 matching trials from the live ClinicalTrials.gov search.

Filters: Intervention: Magnetic Resonance Clear all

Conditions: Prostate Cancer
Interventions: MRI UroNav fusion biopsy; Procedure
Lead sponsor: Kaiser Permanente; Other
Eligibility: 30 Years to 79 Years · Male only
Enrollment: 400 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2014 – 2015
U.S. locations: 2
States / cities: Los Angeles, California • Riverside, California

Conditions: Advanced Lung Non-Small Cell Carcinoma, Recurrent Lung Non-Small Cell Carcinoma, Stage IIIB Lung Non-Small Cell Cancer AJCC v7, Stage IV Lung Non-Small Cell Cancer AJCC v7
Interventions: Biospecimen Collection, Computed Tomography with Contrast, Echocardiography Test, Magnetic Resonance Imaging, Multigated Acquisition Scan, Osimertinib; Procedure · Drug
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2027
U.S. locations: 347
States / cities: Anchorage, Alaska • Fairbanks, Alaska • Fort Smith, Arkansas + 238 more

Conditions: B Acute Lymphoblastic Leukemia, B Lymphoblastic Lymphoma, Central Nervous System Leukemia, Mixed Phenotype Acute Leukemia, Testicular Leukemia
Interventions: Biospecimen Collection, Blinatumomab, Bone Marrow Aspiration, Bone Marrow Biopsy, Bone Scan, Calaspargase Pegol, Computed Tomography, Cyclophosphamide, Cytarabine, Daunorubicin Hydrochloride, Dexamethasone, Doxorubicin Hydrochloride, Inotuzumab Ozogamicin, Leucovorin Calcium, Magnetic Resonance Imaging, Mercaptopurine, Methotrexate, Pegaspargase, Positron Emission Tomography, Prednisolone, Prednisone, Questionnaire Administration, Radiation Therapy, Thioguanine, Vincristine Sulfate; Procedure · Biological · Drug + 2 more
Lead sponsor: Children's Oncology Group; Network
Eligibility: 365 Days to 25 Years
Enrollment: 5,951 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2032
U.S. locations: 203
States / cities: Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 155 more

Conditions: Pancreatic Cancer
Interventions: Synthetic Human Secretin; Drug
Lead sponsor: Columbia University; Other
Eligibility: 18 Years to 75 Years
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2012
U.S. locations: 1
States / cities: New York, New York

Conditions: Dietary Fiber
Interventions: Dietary fiber: 10-25g, Dietary fiber: 5g; Other
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 20 Years to 55 Years
Enrollment: 88 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Chronic Hip Pain
Interventions: MRI; Diagnostic Test
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 20 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2021
U.S. locations: 1
States / cities: New York, New York

Conditions: Metastatic Head and Neck Squamous Cell Carcinoma, Metastatic Squamous Cell Carcinoma in Cervical Lymph Node
Interventions: Computed Tomography, Fluciclovine F18, Positron Emission Tomography; Procedure · Radiation
Lead sponsor: M.D. Anderson Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Houston, Texas

Conditions: Anatomic Stage IV Breast Cancer AJCC v8, Metastatic Triple-Negative Breast Carcinoma, Unresectable Triple-Negative Breast Carcinoma
Interventions: Biopsy, Biospecimen Collection, Celecoxib, Computed Tomography, Interferon Alpha-2, Magnetic Resonance Imaging, Pembrolizumab, Rintatolimod; Procedure · Drug · Biological
Lead sponsor: Roswell Park Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 5 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Buffalo, New York

Conditions: Bladder Urothelial Carcinoma, Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Interventions: Biospecimen Collection, Computed Tomography, Durvalumab, Futibatinib, Magnetic Resonance Imaging, Radical Cystectomy; Procedure · Biological · Drug
Lead sponsor: Yuanquan Yang; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 3
States / cities: Ann Arbor, Michigan • Cleveland, Ohio • Columbus, Ohio

Conditions: Gaucher Disease, Type 3
Interventions: No intervention; Other
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 80 Years
Enrollment: 5 participants
Timeline: 2023 – 2026
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: Lung Non-Small Cell Carcinoma, Stage IIB Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8, Superior Sulcus Lung Carcinoma
Interventions: Atezolizumab, Biopsy, Biospecimen Collection, Carboplatin, Cisplatin, Computed Tomography, Etoposide, External Beam Radiation Therapy, Magnetic Resonance Imaging, Paclitaxel, Pemetrexed, Positron Emission Tomography, Therapeutic Conventional Surgery; Biological · Procedure · Drug + 1 more
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2031
U.S. locations: 46
States / cities: Jonesboro, Arkansas • Tampa, Florida • Boise, Idaho + 41 more

Conditions: Lung Carcinoma, Lung Non-Small Cell Carcinoma, Metastatic Malignant Neoplasm in the Lung, Stage I Lung Cancer AJCC v8, Stage II Lung Cancer AJCC v8, Stage IIIA Lung Cancer AJCC v8
Interventions: Computed Tomography, Magnetic Resonance Imaging, Positron Emission Tomography, Quality-of-Life Assessment, Radiology, Treatment Planning, Stereotactic Body Radiation Therapy, X-Ray Imaging; Procedure · Other · Radiation
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years and older
Enrollment: 70 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2031
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Uterine Fibroids, With Unexplained Infertility
Interventions: ExAblate 2000, Myomectomy; Device · Procedure
Lead sponsor: InSightec; Industry
Eligibility: 21 Years to 40 Years · Female only
Enrollment: 2 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2011
U.S. locations: 6
States / cities: Los Angeles, California • Smyrna, Georgia • Rochester, Minnesota + 3 more

Conditions: Decision Making, Executive Function, Dopamine
Interventions: Tolcapone 200 MG, Functional Magnetic Resonance Imaging (fMRI); Drug · Other
Lead sponsor: University of California, Berkeley; Other
Eligibility: 18 Years to 40 Years
Enrollment: 70 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Berkeley, California

Conditions: Epilepsy, Tumor, Healthy
Interventions: High-density electroencephalogram (HD-EEG); Diagnostic Test
Lead sponsor: Dartmouth-Hitchcock Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 122 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018 – 2024
U.S. locations: 1
States / cities: Lebanon, New Hampshire

Conditions: Type 1 Diabetes, Hypoglycemia Unawareness
Interventions: somatostatin; Drug
Lead sponsor: University of Minnesota; Other
Eligibility: 18 Years to 65 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2017
U.S. locations: 1
States / cities: Minneapolis, Minnesota

Conditions: PTSD, Trauma
Interventions: Estradiol patch, Placebo patch; Drug · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 35 Years · Female only
Enrollment: 127 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Brain Injuries
Interventions: Transcranial Magnetic Stimulation (TMS), Sham TMS; Device · Other
Lead sponsor: Emory University; Other
Eligibility: 18 Years to 85 Years
Enrollment: 64 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2019 – 2023
U.S. locations: 2
States / cities: Atlanta, Georgia

Conditions: Pain Resulting From Bone Metastases
Interventions: ExAblate MRgFUS (Magnetic Resonance guided Focused Ultrasound Surgery); Device
Lead sponsor: InSightec; Industry
Eligibility: 18 Years and older
Enrollment: 17 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2017
U.S. locations: 6
States / cities: Duarte, California • San Francisco, California • Stanford, California + 3 more

Conditions: Movement Disorders
Interventions: MRI; Device
Lead sponsor: National Institute of Neurological Disorders and Stroke (NINDS); NIH
Eligibility: 18 Years to 99 Years
Enrollment: 254 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2022
U.S. locations: 2
States / cities: Bethesda, Maryland • Providence, Rhode Island

Conditions: Intensive Meditation in Novice and Experienced Meditators
Interventions: Advanced multi-component meditation practice; Behavioral
Lead sponsor: Tobias Moeller-Bertram; Industry
Eligibility: 21 Years and older
Enrollment: 21 participants
Timeline: 2022 – 2023
U.S. locations: 1
States / cities: Palm Desert, California

Conditions: Neuroendocrine Tumor
Interventions: Computed Tomography, Gallium Ga 68-DOTA-FAPI-04, Positron Emission Tomography; Procedure · Drug
Lead sponsor: University of Michigan Rogel Cancer Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2027
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Adenosquamous Carcinoma of the Pancreas
Interventions: Minnelide, ECG, CT/MRI, Tumor Biopsy; Drug · Diagnostic Test · Procedure
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 18 Years and older
Enrollment: 16 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2025
U.S. locations: 1
States / cities: Bethesda, Maryland

Conditions: Bradycardia, Slow Heart Beat
Interventions: Implantable Pulse Generator (IPG) and Pacing Leads (wires), Magnetic Resonance Imaging (MRI) scan; Device · Other
Lead sponsor: Medtronic Cardiac Rhythm and Heart Failure; Industry
Eligibility: Not listed
Enrollment: 484 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2007 – 2010
U.S. locations: 15
States / cities: Redwood City, California • Salinas, California • Orlando, Florida + 12 more

Search by objective public record fields.

Comparison of MRI Fusion Biopsy Techniques in Men With Elevated PSA and Prior Negative Prostate Biopsy

Testing Osimertinib as a Treatment for Lung Cancers With an EGFR Exon 20 Change

Inotuzumab Ozogamicin and Post-Induction Chemotherapy in Treating Patients With High-Risk B-ALL, Mixed Phenotype Acute Leukemia, and B-LLy

Secretin-enhanced Magnetic Resonance Cholangiopancreatography (S-MRCP) and Pancreatic Function Following Surgery

Dietary Fiber Effects on the Microbiome and Satiety

Maveric Magnetic Resonance Imaging Used to Study Detailed Bone Apposition and Fixation of the Stryker Trident II Tritanium System

Fluciclovine F18 PET/CT in Identifying the Origin of Head and Neck Squamous Cell Carcinoma in Patients With Metastatic Cervical Nodal Disease

Rintatolimod, Celecoxib and Interferon Alpha 2b With Pembrolizumab For the Treatment of Patients With Metastatic or Unresectable Triple Negative Breast Cancer

Futibatinib in Combination With Durvalumab Prior to Cystectomy for the Treatment of Muscle-Invasive Bladder Cancer Patients Who Are Ineligible for Cisplatin-based Therapy

MAGNETIC RESONANCE SPECTROSCOPY BIOMARKERS IN TYPE 3 GAUCHER DISEASE (GD3)

Testing the Addition of an Immunotherapy Drug, Atezolizumab, to the Usual Chemotherapy Treatment During Radiation Therapy for Superior Sulcus Non-small Cell Lung Cancer

Stereotactic Body Radiation Therapy Planning With Artificial Intelligence-Directed Dose Recommendation for Treatment of Primary or Metastatic Lung Tumors, RAD-AI Study

ExAblate Treatment of Uterine Fibroids for Fertility Enhancement

Dopaminergic Mechanisms Underlying Human Social Behavior

High-density EEG in Neurological Disorders

Measurement of Glucose Metabolism in Humans Using Magnetic Resonance at 4 Tesla. Substudy: Hypoglycemia Unawareness

Neuroendocrine Risk for PTSD in Women

Cortical Contributions to Motor Sequence Learning

ExAblate Treatment of Metastatic Bone Tumors for the Palliation of Pain

Neurobiology of Functional Movement Disorder and Non-Epileptic Seizures

Integrating Magnetic Imaging With Rich Phenotypes

An Investigational Scan ([68Ga] Ga-FAPI-04 PET/CT) for the Imaging of Patients With High-Grade Neuroendocrine Cancer

Superenhancer Inhibitor Minnelide in Advanced Refractory Adenosquamous Carcinoma of the Pancreas (ASCP)

EMRI SureScan™ Clinical Study